查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930112

全球心血管药物市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Cardiovascular Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 139 Pages | 商品交期: 请询问到货日

价格

心血管药物市场成长因素

全球心血管药物市场是製药业最成熟、最重要的细分市场之一，其成长主要受全球心血管疾病负担日益加重的驱动。心血管疾病（CVD）仍然是全球首要死因，高血压、冠状动脉疾病、心律不整、高血脂、心肌梗塞和中风等疾病对医疗保健系统造成了重大影响。

市场规模及预测

根据 Fortune Business Insights 预测，2025 年全球心血管药物市场规模预估为 615.8 亿美元。预计到 2026 年将成长至 639.7 亿美元，到 2034 年将达到 868.5 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 3.90%。

这种稳定成长反映了心血管疾病的慢性特征、长期药物依赖性、疾病意识的提高以及药物研发的持续创新。

市场概况及疾病负担

心血管疾病 (CVD) 指的是心臟和血管的疾病，包括心臟病发作和中风等危及生命的疾病。根据世界卫生组织 (WHO) 统计，心臟病发作和中风占心血管疾病死亡人数的五分之四。缺乏运动、不健康饮食、肥胖、吸烟、糖尿病和高血压等生活方式因素持续加速着该疾病在全球的流行。

高风险族群通常会出现高血压、高胆固醇、高血糖和肥胖等症状，从而推动了对心血管药物的长期需求。

主要市场驱动因子

心血管药物市场的主要驱动因素之一是人们对心血管健康的日益重视以及诊断和治疗率的提高。同时，持续的研发正在推出更先进、更有效的药物疗法。

由百时美施贵宝和辉瑞公司共同开发的重磅药物，例如艾乐妥（阿哌沙班），在预防中风和心臟病方面展现出卓越的临床疗效，显着提升了市场收入。不断增长的未满足治疗需求，尤其是在老龄化社会中，进一步支撑了市场的持续成长。

市场区隔分析

依药物类型划分

依药物类型，市场可细分为降血压药、降血脂药、抗凝血药、抗血小板药和其他药物。

抗凝血药物细分市场占主导地位，预计2026年将占约50.44%的市场。其主导地位主要得益于高昂的药价、广泛的临床应用以及艾乐妥等领先品牌的强劲销售。抗高血压药物市场占有率位居第二，但由于仿製药的普及，其增长速度正在放缓。

依疾病分类

依疾病分类，市场可分为高血压、高血脂、冠状动脉疾病、心律不整和其他疾病。

高血压市场由于其全球高发病率以及作为心臟病和中风的主要危险因素，预计到2026年将占市场占有率的31.04%，复合年增长率显着。

依分销管道分类

依分销管道分类，市场可分为医院药局、零售药局、线上药局和其他通路。

医院药局领域将引领市场，预计到 2026 年将占 46.84% 的市场占有率，因为心血管药物通常是在医院确诊后开立的。由于数位化和便利性的进步，预计线上药局将拥有最高的成长率。

区域分析

预计北美将在2025年占心血管药物市场的主导地位，市占率达45.16%，并在2026年创造287.8亿美元的收入。光是美国市场预计到2026年就将达到266.8亿美元，主要得益于高发病率和强劲的研发活动。

预计亚太地区将实现最快成长，其中日本预计到2026年将达到53.1亿美元，中国预计达到37.3亿美元，印度预计达到18.3亿美元。欧洲预计也将保持稳定成长，这主要得益于较高的心血管疾病死亡率，尤其是在英国、法国和德国。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 主要国家主要心血管疾病的盛行率
  • 在开发产品分析
  • 主要产业趋势：併购等
  • 新产品上市
  • 主要国家的监管环境
  • 主要国家的健保报销情况
  • 新型药物研发进展治疗学

第五章 全球心血管药物市场分析：洞察与预测（2021-2034）

  • 主要分析结果/摘要
  • 市场分析、洞察与预测：依药物类型划分
    • 抗高血压药
    • 降血脂药
    • 抗凝血药
    • 抗血小板药
    • 其他
  • 市场分析、洞察与预测：依疾病划分
    • 高血压
    • 高血脂症
    • 冠状动脉疾病患者
    • 心律不整
    • 其他
  • 市场分析、洞察与预测：依销售管道划分
    • 医院药房
    • 零售药房
    • 线上药房
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美心血管药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲心血管药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国王国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太心血管药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲心血管药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东与非洲心血管药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 主要的产业趋势
  • 世界市场占有率分析(2025年)
  • 竞争形势仪表板
  • 主要企业的比较分析
  • 企业简介
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Merck &Co., Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Other Prominent Players
Product Code: FBI100379

Growth Factors of cardiovascular drugs Market

The global cardiovascular drugs market represents one of the most established and essential segments of the pharmaceutical industry, driven by the growing burden of heart and blood vessel-related disorders worldwide. Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, with conditions such as hypertension, coronary artery disease, arrhythmia, hyperlipidemia, myocardial infarction, and stroke significantly impacting healthcare systems.

Market Size and Forecast

According to Fortune Business Insights, the global cardiovascular drugs market size was valued at USD 61.58 billion in 2025. The market is projected to grow to USD 63.97 billion in 2026 and further reach USD 86.85 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 3.90% during the forecast period (2026-2034).

The steady growth reflects the chronic nature of cardiovascular diseases, long-term drug dependency, increasing disease awareness, and continued innovation in drug development.

Market Overview and Disease Burden

Cardiovascular diseases are disorders of the heart and blood vessels and include life-threatening conditions such as heart attacks and strokes. According to the World Health Organization (WHO), four out of five cardiovascular disease deaths are caused by heart attacks and strokes. Lifestyle factors such as physical inactivity, unhealthy diets, obesity, smoking, diabetes, and high blood pressure continue to accelerate disease prevalence globally.

Individuals at high risk often exhibit elevated blood pressure, cholesterol, blood glucose levels, and obesity, increasing the long-term demand for cardiovascular therapeutics.

Key Market Drivers

One of the primary drivers of the cardiovascular drugs market is increased awareness of cardiovascular health, along with improved diagnosis and treatment rates. In parallel, continuous research and development (R&D) has led to the introduction of advanced and more effective drug therapies.

Blockbuster drugs such as Eliquis (apixaban), developed by Bristol-Myers Squibb Company and Pfizer Inc., have demonstrated superior clinical outcomes in preventing strokes and heart attacks, significantly boosting market revenues. The growing unmet treatment need, especially in aging populations, further supports sustained market growth.

Market Segmentation Analysis

By Drug Type

Based on drug type, the market is segmented into antihypertensive, antihyperlipidemic, anticoagulants, antiplatelet drugs, and others.

The anticoagulants segment dominates the market, accounting for an estimated 50.44% market share in 2026. This dominance is driven by high drug prices, widespread clinical use, and strong sales of leading brands such as Eliquis. The antihypertensive segment holds the second-largest share, although growth is moderated by the widespread availability of generic drugs.

By Disease Indication

By disease indication, the market is segmented into hypertension, hyperlipidemia, coronary artery disease, arrhythmia, and others.

The hypertension segment is anticipated to grow at a significant CAGR, holding a 31.04% share in 2026, supported by its high global prevalence and its role as a major risk factor for heart attacks and strokes.

By Distribution Channel

In terms of distribution, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment leads the market, accounting for 46.84% share in 2026, as cardiovascular drugs are often prescribed following hospital-based diagnosis. Online pharmacies are expected to witness the highest growth rate due to increasing digital adoption and convenience.

Regional Analysis

North America dominated the cardiovascular drugs market with a 45.16% share in 2025, generating USD 28.78 billion in revenue in 2026. The U.S. market alone is projected to reach USD 26.68 billion by 2026, driven by high disease prevalence and strong R&D activity.

The Asia Pacific region is expected to witness the fastest growth, with Japan reaching USD 5.31 billion, China USD 3.73 billion, and India USD 1.83 billion by 2026. Europe is also projected to grow steadily due to high cardiovascular mortality rates, particularly in the U.K., France, and Germany.

Competitive Landscape

The market is dominated by major pharmaceutical players such as Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, AstraZeneca, Novartis AG, and Sanofi. The industry remains mature, highly competitive, and strongly influenced by generic drug penetration.

Conclusion

In conclusion, the global cardiovascular drugs market is expected to grow steadily from USD 61.58 billion in 2025 to USD 86.85 billion by 2034, supported by rising cardiovascular disease prevalence, strong demand for anticoagulants, continuous drug innovation, and expanding healthcare access. Despite generic competition, the market will continue to remain a critical pillar of the global pharmaceutical industry due to the chronic and life-threatening nature of cardiovascular diseases.

Segmentation By Drug Type

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments Such as Mergers & Acquisitions
  • 4.4. New Product Launches
  • 4.5. The Regulatory Scenario in Key Countries
  • 4.6. Reimbursement Scenario by Key Countries
  • 4.7. Advances in R&D for Novel Therapeutics

5. Global Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Type
    • 5.2.1. Antihypertensive
    • 5.2.2. Antihyperlipidemic
    • 5.2.3. Anticoagulants
    • 5.2.4. Antiplatelet Drugs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Hypertension
    • 5.3.2. Hyperlipidemia
    • 5.3.3. Coronary Artery Disease
    • 5.3.4. Arrhythmia
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Drug Type
    • 6.2.1. Antihypertensive
    • 6.2.2. Antihyperlipidemic
    • 6.2.3. Anticoagulants
    • 6.2.4. Antiplatelet Drugs
    • 6.2.5. Others
  • 6.3. Market Analysis - By Disease Indication
    • 6.3.1. Hypertension
    • 6.3.2. Hyperlipidemia
    • 6.3.3. Coronary Artery Disease
    • 6.3.4. Arrhythmia
    • 6.3.5. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Drug Type
    • 7.2.1. Antihypertensive
    • 7.2.2. Antihyperlipidemic
    • 7.2.3. Anticoagulants
    • 7.2.4. Antiplatelet Drugs
    • 7.2.5. Others
  • 7.3. Market Analysis - By Disease Indication
    • 7.3.1. Hypertension
    • 7.3.2. Hyperlipidemia
    • 7.3.3. Coronary Artery Disease
    • 7.3.4. Arrhythmia
    • 7.3.5. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Drug Type
    • 8.2.1. Antihypertensive
    • 8.2.2. Antihyperlipidemic
    • 8.2.3. Anticoagulants
    • 8.2.4. Antiplatelet Drugs
    • 8.2.5. Others
  • 8.3. Market Analysis - By Disease Indication
    • 8.3.1. Hypertension
    • 8.3.2. Hyperlipidemia
    • 8.3.3. Coronary Artery Disease
    • 8.3.4. Arrhythmia
    • 8.3.5. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Drug Type
    • 9.2.1. Antihypertensive
    • 9.2.2. Antihyperlipidemic
    • 9.2.3. Anticoagulants
    • 9.2.4. Antiplatelet Drugs
    • 9.2.5. Others
  • 9.3. Market Analysis - By Disease Indication
    • 9.3.1. Hypertension
    • 9.3.2. Hyperlipidemia
    • 9.3.3. Coronary Artery Disease
    • 9.3.4. Arrhythmia
    • 9.3.5. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Drug Type
    • 10.2.1. Antihypertensive
    • 10.2.2. Antihyperlipidemic
    • 10.2.3. Anticoagulants
    • 10.2.4. Antiplatelet Drugs
    • 10.2.5. Others
  • 10.3. Market Analysis - By Disease Indication
    • 10.3.1. Hypertension
    • 10.3.2. Hyperlipidemia
    • 10.3.3. Coronary Artery Disease
    • 10.3.4. Arrhythmia
    • 10.3.5. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country/ sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Bristol-Myers Squibb Company
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. Pfizer Inc.
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Bayer AG
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Janssen Pharmaceuticals, Inc.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. AstraZeneca
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Sanofi
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Novartis AG
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Merck & Co., Inc.
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. Gilead Sciences, Inc.
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. F. Hoffmann-La Roche Ltd
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)

List of Tables

  • Table 1: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 6: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 10: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 14: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 18: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 22: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiovascular Drugs Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025-2034
  • Figure 3: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antihypertensive, 2021-2034
  • Figure 4: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antihyperlipidemic, 2021-2034
  • Figure 5: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Anticoagulants, 2021-2034
  • Figure 6: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antiplatelet Drugs, 2021-2034
  • Figure 7: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 8: Global Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025-2034
  • Figure 9: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hypertension, 2021-2034
  • Figure 10: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hyperlipidemia, 2021-2034
  • Figure 11: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Coronary Artery Disease, 2021-2034
  • Figure 12: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Arrhythmia, 2021-2034
  • Figure 13: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 14: Global Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 15: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 16: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 17: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 18: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 19: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Mod5, 2021-2034
  • Figure 20: Global Cardiovascular Drugs Market Value (US$ Mn), by Region, 2025-2034
  • Figure 21: North America Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 22: North America Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 23: North America Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 24: North America Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 25: North America Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 26: North America Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: North America Cardiovascular Drugs Market Value (US$ Mn), By Country, 2025-2034
  • Figure 28: North America Cardiovascular Drugs Market Value Share (%), By Country, 2025
  • Figure 29: Europe Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 30: Europe Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 31: Europe Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 32: Europe Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Europe Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 34: Europe Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 36: Europe Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 39: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 42: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 43: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 44: Asia Pacific Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 46: Latin America Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 47: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 48: Latin America Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 49: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 50: Latin America Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 51: Latin America Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 52: Latin America Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 53: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 54: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 55: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 57: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 59: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 60: Middle East & Africa Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 61: Global Cardiovascular Drugs Market Share (%), By Company, 2025